AN2 Therapeutics Reports Narrower Q1 Loss, $85M Cash, and Extends Runway to 2029 with Multiple Pipeline Advancements

summarizeSummary

AN2 Therapeutics reported a narrower net loss for Q1 2026, ending the quarter with $85.3 million in cash and investments, extending its operational runway into 2029. The company also provided positive updates on the advancement of several clinical and preclinical programs.

check_boxKey Events

• Q1 Financial Results

  Reported a net loss of $10.0 million for Q1 2026, a reduction from $10.6 million in Q1 2025.

• Strong Cash Position & Runway

  Ended Q1 2026 with $85.3 million in cash, cash equivalents, and investments, projecting a cash runway into 2029.

• Pipeline Advancement - Polycythemia Vera

  Oral epetraborole is advancing into a Phase 2 trial for polycythemia vera, with initiation planned for Q3 2026 and data readouts expected from Q4 2026.

• Pipeline Advancement - M. abscessus

  Commenced a Phase 2 investigator-initiated trial of epetraborole for M. abscessus lung disease, with topline results anticipated in late 2027.

auto_awesomeAnalysis

This filing is highly important for AN2 Therapeutics as it provides a strong financial update, confirming a narrower net loss and a robust cash position of $85.3 million. Crucially, this cash is projected to fund operations into 2029, significantly de-risking the company's financial outlook following recent dilutive financings. The report also details the advancement of multiple key pipeline programs, including oral epetraborole into Phase 2 for polycythemia vera and M. abscessus lung disease, and AN2-502998 for Chagas disease, alongside a new oncology candidate. This combination of financial stability and clinical progress provides a clear positive signal for investors.